Overview

A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment

Status:
Completed
Trial end date:
2010-06-18
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the pharmacokinetics of ASP1941 in type 2 diabetes mellitus patients with normal renal function and those with mild or moderate renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Ipragliflozin